Anti-tumor properties of cis-resveratrol methylated analogs in metastatic mouse melanoma cells

Molecular and Cellular Biochemistry

Volumn 402, Issue 1-2, 2015, Pages 83-91

  Morris, Valery L ^a   Toseef, Tayyaba ^a   Nazumudeen, Fathima B ^a   Rivoira, Christian ^a   Spatafora, Carmela ^b   Tringali, Corrado ^b   Rotenberg, Susan A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anti cancer; Cell motility; PHIP; Polymethoxystilbenes; Proliferation; tubulin

Indexed keywords

3,5,4' TRIHYDROXYSTILBENE; 3,5,4' TRIMETHOXY STILBENE; 3,5,4' TRIMETHOXYSTILBENE; ANTINEOPLASTIC AGENT; BETA TUBULIN; PLECKSTRIN HOMOLOGY DOMAIN INTERACTING PROTEIN; PROTEIN; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; METASTATIC MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; IC50; MELANOMA, EXPERIMENTAL; METASTASIS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL MOVEMENT; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; INHIBITORY CONCENTRATION 50; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; STILBENES;

EID: 84925502006     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2316-8     Document Type: Article

References (44)

1. Muthusamy V, Piva TJ (2011) Melanoma cell signaling: looking beyond RAS-RAF-MEK skin cancers. In: La Porta C (ed) Risk factors, prevention, and therapy. InTech, Rijeka
2. Conde-Perez A, Larue L (2013) Human relevance of NRAS/BRAF mouse melanoma models. Eur J Cell Biol 93:82–86
3. Chillemi R, Sciuto S, Spatafora C, Tringali C (2007) Anti-tumor properties of stilbene-based resveratrol analogues: recent results. Nat Prod Commun 2:499–513
4. Bhattacharya S, Darjatmoko SR, Polans AS (2011) Resveratrol modulates the malignant properties of cutaneous melanoma via changes in the activation and attenuation of the anti-apoptotic proto-oncogenic protein Akt/PKB. Melanoma Res 21:180–187
5. Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS (2012) Enhancing melanoma treatment with resveratrol. J Surg Res 172:109–115
6. Spatafora C, Tringali C (2012) Natural-derived polyphenols as potential anticancer agents. Anticancer Agents Med Chem 12:902–918
7. Ahmad KA, Clement M-V, Pervaiz S (2003) Pro-oxidant activity of low doses of resveratrol inhibits hyfrogen peroxide-induced apoptosis. Ann NY Acad Sci 1010:365–373
8. Gusman J, Malonne H, Atassi G (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22:1111–1117
9. Zhuang H, Kim YS, Koehler RC, Dore S (2003) Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann NY Acad Sci 993:276–286
10. Qian YP, Cai YJ, Fan GJ, Wei QY, Yang J, Zheng LF, Li XZ, Fang JG, Zhou B (2009) Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol. J Med Chem 52:1963–1974
11. Vitale N, Kisslinger A, Paladino S, Procaccini C, Matarese G, Pierantoni GM, Mancini FP, Tramontano D (2013) Resveratrol couples apoptosis with autophagy in UVB-irradiated HaCaT cells. PLoS One 8(11):e80728
12. Madlener S, Saiko P, Vonach C, Viola K, Huttary N, Stark N, Popescu R, Gridling M, Vo NT, Herbacek I, Davidovits A, Giessrigl B, Venkateswarlu S, Geleff S, Jäger W, Grusch M, Kerjaschki D, Mikulits W, Golakoti T, Fritzer-Szekeres M, Szekere T, Krupitza G (2010) Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. Br J Cancer 102:1361–1370
13. Wu Y, Liu F (2013) Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment. Anticancer Agents Med Chem 13:1032–1038
14. Azios NG, Dharmawardhane SF (2005) Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 7:128–140
15. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ (2003) Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 1637:59–69
16. Das J, Pany S, Majhi A (2011) Chemical modifications of resveratrol for improved protein kinase C alpha activity. Bioorg Med Chem 19:5321–5333
17. Saiko P, Graser G, Giessrigl B, Steinmann MT, Schuster H, Lackner A, Grusch M, Krupitza G, Jaeger W, Somepalli V, Golakoti T, Fritzer-Szekeres M, Szekeres T (2013) Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. Invest New Drugs 31:1115–1124
18. Wang M, Yu T, Zhu C, Sun H, Qiu Y, Zhu X, Li J (2014) Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr Cancer 66:435–440
19. Chabert P, Fougerousse A, Brouillard R (2006) Anti-mitotic properties of resveratrol analog (Z)-3,5,4′-trimethoxystilbene. BioFactors 27:37–46
20. Fang Y, Bradley MJ, Cook KM, Herrick EJ, Nicholl MB (2013) A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J Surg Res 183:645–653
21. Shih A, Zhang S, Cao HJ, Boswell S, Wu Y-H, Tang H-Y, Lennartz MR, Davis FB, Davis P, Lin H-Y (2004) Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-α. Mol Cancer Ther 3:1355–1363
22. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506
23. Walle T (2011) Bioavailability of resveratrol. Ann NY Acad Sci 1215:9–15
24. Weng C-J, Wu C-F, Huang H-W, Wu C-H, Ho CT, Yen G-C (2010) Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem 58:2886–2894
25. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay J-F, Brouillard R, Raul F (2003) Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107:189–196
26. Mazue F, Colin D, Gobbo J, Wegner M, Rescifina A, Spatafora C, Fasseur D, Delmas D, Meunier P, Tringali C, Latruffe N (2010) Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs. Eur J Med Chem 45:2972–2980
27. Gosslau A, Chen M, Ho CT, Chen KY (2005) A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts. Br J Cancer 92:513–521
28. Wong Y, Osmond G, Brewer KI, Tyler DS, Andrus MB (2010) Synthesis of 4′-ester analogs of resveratrol and their evaluation in malignant melanoma and pancreatic cell lines. Bioorg Med Chem Lett 20:1198–1201
29. Roman BI, De Coen LM, Mortier STFC, De Ryck T, Vanhoecke BWA, Katritzky AR, Bracke ME, Stevens CV (2013) Design, synthesis, and structure-activity relationships of some novel, highly potent anti-invasive (E)- and (Z)-stilbenes. Bioorg Med Chem 21:5054–5063
30. Raz A, Mclellan WL, Hart IR, Bucana CD, Hoyer LC, Sela B-A, Dragsten P, Fidler IJ (1980) Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res 40:1645–1651
31. Bennett DC, Cooper PJ, Hart IR (1987) A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39:414–418
32. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN (2004) Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23:2347–2356
33. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira S-M, Wymann MP (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7:601–613
34. Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C (2007) Anti-proliferative activity of methylated analogues of E- and Z-resveratrol. Z Naturforsch C 62:189–195
35. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E (1991) Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34:2579–2588
36. Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E (1992) Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)etheanes potential cytotoxic and antimitotic agents. J Med Chem 35:2293–2306
37. Zaki MA, Balachandran P, Khan S, Wang M, Mohammed R, Hetta MH, Pasco DS, Muhammad I (2013) Cytotoxicity and modulation of cancer-related signaling by (Z)- and (E)-3,4,3′,5′-tetramethoxystilbene isolated from Eugenia rigida. J Nat Prod 76:679–684
38. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R (2007) The use of Alamar Blue assay for quantitative analysis of viability, migration, and invasion of choriocarcinoma cells. Hum Reprod 22:1304–1309
39. De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G, Venna S, Rangel J, Climent J, Tamguney TMM, Thummala S, Yong S, Leong SPL, Hagg C, Billings P, Miller JR, Sagebiel RW, Debs R, Kashani-Sabet M (2012) Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proc Natl Acad Sci 109:7067–7072
40. Cardile V, Lombardo L, Spatafora C, Tringali C (2005) Chemo-enzymatic synthesis and growth-inhibition activity of resveratrol analogues. Bioorg Chem 33:22–33
41. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M (2005) Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol Pharm 67:1451–1459
42. Ballestrem C, Wehrle-Haller B, Hinz B, Imhof BA (2000) Actin-dependent lamellipodia formation and microtubule-dependent tail retraction control-directed cell migration. Mol Biol Cell 11:2999–3012
43. Huff LM, Sackett DL, Poruchynsky MS, Fojo T (2010) Microtubule disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 70:5870–5879
44. Cichocki M, Baer-Dubowska W, Wierzchowski M, Murias M, Jodynis-Liebert J (2014) 3,4,5,4′-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF-κB, AP-1, and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen. Mol Cell Biochem 391:27–35